REG - N4 Pharma PLC - Launch of Nuvec® Oncology Treatment Programme

N4 PharmaAnnouncement

09/11/2020 07:06

RNS Number : 5684E
  
N4 Pharma PLC
  
09 November 2020
  
 

9 November 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
 
Launch of Nuvec® Oncology Treatment Programme
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has appointed Nanomerics Limited ("Nanomerics") to investigate the potential utility of Nuvec® in cancer therapy. The project will explore the role of Nuvec® as a delivery system for DNA and SiRNA. The initial aim is to test a silica based, delivery system in a proof of concept preclinical tumour model (the "Oncology Programme").
 
Based at UCL's School of Pharmacy, Nanomerics' scientists have been developing and evaluating gene delivery systems for over two decades including the delivery of genes to tumours. Having worked with the Company since mid-February, the team at Nanomerics has applied its existing gene therapy delivery expertise with what it has learnt about Nuvec® in scoping out the two stage work programme to assess the potential for Nuvec® as a delivery system for oncology therapeutics.
 
Stage one will focus on the formulation of Nuvec® with a therapeutic DNA plasmid. Stage two will see the candidate formulation evaluated in vivo in a subcutaneous tumour model to examine tumour regression following multiple local or systemic injections.
 
The two stage programme, which is commencing immediately, is expected to take up to twelve months and will run in parallel to the Company's ongoing vaccine delivery work.
 
Nigel Theobald, Chief Executive Officer of the Company, commented:
 
"We are very excited to commence our Oncology Programme with Nanomerics in what could be a third commercial application for Nuvec® in a hugely significant market. Not only could Nuvec® have the potential to deliver therapeutic nucleic acids to target tumours, but also due to the structure of Nuvec® with its hollow core, it is feasible that it could be developed as a combination product whereby it carries an external nucleic acid load and an internal small molecule chemotherapeutic. Such potential could make Nuvec® very attractive as a possible delivery system for oncology therapeutics."
 
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via IFC Advisory




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker


















IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen                                                  


Tel: +44(0)20 3934 6630



 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RESUPGGUGUPUGQQ